Wegovy vs Mounjaro/Zepbound: Mechanism, Korea/U.S. Pricing, and Investor Takeaways at a Glance
At the center of today’s weight-loss and metabolic-disease care are GLP-1 class (and dual-agonist) injectables. Below we distill the essentials comparing Novo Nordisk’s Wegovy (semaglutide) with Eli Lilly’s Mounjaro/Zepbound (tirzepatide) , then add investor angles on both companies and Korea-focused ripple effects across healthcare. Note for international readers: figures and policy/pricing references are Korea-facing and current as of Aug 29, 2025. 🎯 Key Takeaways ✅ Mechanism: Wegovy = single GLP-1; Mounjaro/Zepbound = dual GIP + GLP-1 agonist ✅ Korea pricing (ex-factory): From August, Wegovy moved to dose-tiered pricing (0.25 mg ≈ ₩216,000–₩223,200). Mounjaro: 2.5 mg ₩278,066; 5 mg ₩369,307. ✅ Investing: Lilly and Novo keep expanding capacity and growing sales. Risks include rich valuation, competition, and progress on oral programs. • Healthcare spillovers (Korea view): A...